Echo IQ (EIQ) Q1 2027 TU earnings summary

Executive summary

• US commercial momentum strengthened, with EchoSolv AS full-result assessments up ~193% YoY in Q1 and ~406% for 9M CY26.

• Priorities are converting US hospital engagement into contracted deployments and recurring revenue while progressing EchoSolv HF regulatory review and broader cardiovascular AI development.

• A$110m institutional placement lifted cash to A$107.8m at 30 September 2026, supporting commercial expansion and product development.

Financial highlights

• Net cash used in operating activities was A$5.876m for the quarter; investing outflows were A$0.551m.

• Financing inflows were A$105.524m, comprising A$110m from the placement and A$1.298m from option exercises, less A$5.774m of transaction costs.

• Cash and cash equivalents were A$107.784m at quarter end, versus A$8.712m at the start of the period.

Outlook and guidance

• December-quarter priorities include converting the US pipeline into contracted enterprise deployments, growing EchoSolv AS utilisation and recurring assessment volumes, and progressing technical integrations.

• Focus also includes advancing the EchoSolv HF regulatory pathway, clinical and health-economic evidence, reimbursement opportunities, Pro Medicus collaboration and Advara dataset implementation.

• Management plans to build a scalable US business around FDA-cleared EchoSolv AS while pursuing additional cardiovascular indications.